MY167883A - Dry-coated tablet containing tegafur, gimeracil and oteracil potassium - Google Patents

Dry-coated tablet containing tegafur, gimeracil and oteracil potassium

Info

Publication number
MY167883A
MY167883A MYPI2013702158A MYPI2013702158A MY167883A MY 167883 A MY167883 A MY 167883A MY PI2013702158 A MYPI2013702158 A MY PI2013702158A MY PI2013702158 A MYPI2013702158 A MY PI2013702158A MY 167883 A MY167883 A MY 167883A
Authority
MY
Malaysia
Prior art keywords
gimeracil
dry
coated tablet
oteracil potassium
tablet containing
Prior art date
Application number
MYPI2013702158A
Inventor
Takumi Okamoto
Takashi Yoshizawa
Yoshito Ohnishi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MY167883A publication Critical patent/MY167883A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil and (c) oteracil potassium; and an outer shell.
MYPI2013702158A 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium MY167883A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011116884 2011-05-25

Publications (1)

Publication Number Publication Date
MY167883A true MY167883A (en) 2018-09-26

Family

ID=47217314

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013702158A MY167883A (en) 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium

Country Status (16)

Country Link
US (1) US20140335174A1 (en)
EP (1) EP2716290B1 (en)
JP (2) JP5689173B2 (en)
KR (2) KR101869127B1 (en)
AU (1) AU2012259803B2 (en)
BR (1) BR112013030093B1 (en)
CA (1) CA2836865C (en)
ES (1) ES2671926T3 (en)
IL (1) IL229372B (en)
MX (1) MX353289B (en)
MY (1) MY167883A (en)
PH (1) PH12013502323A1 (en)
RU (1) RU2601620C2 (en)
SG (2) SG10201505503WA (en)
TW (2) TWI488659B (en)
WO (1) WO2012161240A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353289B (en) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium.
CN107837273A (en) * 2016-09-18 2018-03-27 江苏金甙生物技术有限公司 A kind of enteric tegafur, gimeracil and oteracil potassium sustained release preparation and preparation method thereof
CN107865871B (en) * 2016-09-23 2021-09-03 江苏恒瑞医药股份有限公司 Tegiloi composition and preparation method thereof
CN106619689B (en) * 2016-12-30 2018-05-01 陈晓华 It is a kind of for the pharmaceutical composition for the treatment of cancer, kit and its application
AU2020347662A1 (en) * 2019-09-13 2022-03-31 Meiji Co., Ltd. Solid food and solid milk
KR20250022143A (en) * 2022-06-10 2025-02-14 다이호야쿠힌고교 가부시키가이샤 Pharmaceutical composition containing pimitespip

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015B1 (en) * 1991-05-27 1998-11-11 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
JP2002505269A (en) * 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ Rapidly disintegrating tablets
JP5178982B2 (en) * 2000-05-18 2013-04-10 セリックス， インコーポレイテッド Encapsulation of the toxic core in a non-toxic region in an oral dosage form
JPWO2003028706A1 (en) * 2001-09-28 2005-01-13 株式会社三和化学研究所 Nucleated fast-disintegrating molded product
JP2005512997A (en) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ Tamsulosin tablets
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
CN1761665A (en) * 2003-03-14 2006-04-19 大鹏药品工业株式会社 Antitumor effect potentiator and antitumor agent
AU2004275569B2 (en) * 2003-09-29 2011-04-21 Cipla Limited Pharmaceutical formulation with improved stability
CN100333726C (en) 2004-12-23 2007-08-29 鲁南制药集团股份有限公司 Disintegration piece taken through oral cavity containing Gimeracil and Oteracil Potassium with fluorine being added
CN101155600B (en) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 Radiation Therapy Booster
JP4994618B2 (en) * 2005-08-11 2012-08-08 学校法人北里研究所 Chemoradiation with TS-1 / camptothecins
WO2009084216A1 (en) * 2007-12-27 2009-07-09 Taiho Pharmaceutical Co., Ltd. Oral powder and granular antitumor agent
TWI468188B (en) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
KR100934876B1 (en) 2008-01-31 2010-01-06 성균관대학교산학협력단 Plating method of LIA process
CN101380327B (en) * 2008-10-09 2011-01-26 北京恒瑞康达医药科技发展有限公司 Anti-cancer composite sustained-release composition and preparation method thereof
JP5553522B2 (en) 2009-03-31 2014-07-16 大鵬薬品工業株式会社 Pharmaceutical composition for oral administration
CA2761243A1 (en) * 2009-05-12 2010-11-18 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
CN101711765B (en) * 2009-10-31 2011-03-23 山东新时代药业有限公司 Dispersing tablet containing tegafur, gimeracil and oteracil potassium
MX353289B (en) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium.
CN102614183B (en) * 2012-03-05 2013-10-30 齐鲁制药(海南)有限公司 Oral preparation containing tegafur, gimeracil and oteracil potassium

Also Published As

Publication number Publication date
KR101869127B1 (en) 2018-06-19
JP5689173B2 (en) 2015-03-25
CA2836865A1 (en) 2012-11-29
BR112013030093B1 (en) 2019-12-10
TWI566787B (en) 2017-01-21
TW201529100A (en) 2015-08-01
RU2601620C2 (en) 2016-11-10
JP5769853B2 (en) 2015-08-26
IL229372A0 (en) 2014-01-30
MX2013013563A (en) 2013-12-16
EP2716290A1 (en) 2014-04-09
IL229372B (en) 2018-12-31
SG10201505503WA (en) 2015-09-29
JP2014218523A (en) 2014-11-20
SG194922A1 (en) 2013-12-30
KR20140037879A (en) 2014-03-27
TW201300141A (en) 2013-01-01
MX353289B (en) 2018-01-05
EP2716290A4 (en) 2014-11-26
US20140335174A1 (en) 2014-11-13
CA2836865C (en) 2018-02-27
KR20170072959A (en) 2017-06-27
EP2716290B1 (en) 2018-03-14
RU2013157528A (en) 2015-06-27
AU2012259803B2 (en) 2016-03-17
NZ617625A (en) 2015-10-30
WO2012161240A1 (en) 2012-11-29
JPWO2012161240A1 (en) 2014-07-31
TWI488659B (en) 2015-06-21
BR112013030093A2 (en) 2016-09-20
PH12013502323A1 (en) 2014-01-06
ES2671926T3 (en) 2018-06-11

Similar Documents

Publication Publication Date Title
ME03347B (en) ANTIPEST COMPOSITIONS CONSISTING OF AN ACTIVE AGENT OF ISOXAZOLINE, ASSOCIATED PROCESSES AND USES
MX347260B (en) Encapsulates.
PH12013502323A1 (en) Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
EA201170271A1 (en) MICROCAPSULES CONTAINING ACTIVE INGREDIENTS AND METAL OXIDE SHELL, METHOD OF THEIR RECEPTION AND THEIR APPLICATION
PH12013501345A1 (en) Tamper resistant solid oral dosage forms
GB201106750D0 (en) Novel compounds
PH12015500900B1 (en) A stabilized pemetrexed formulation
DK2773633T3 (en) Heterocyclic compounds, medicaments containing the compounds, their use and processes for their preparation.
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
NZ612722A (en) Hop extract oxidation-reaction product, preparing method thereof and use thereof
AU2012259803A1 (en) Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
PH12013501552A1 (en) Oral care compositions
PH12016500174A1 (en) Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
WO2013056888A3 (en) Hair styling composition
EA201301355A1 (en) COMPOSITION AND TABLET CONTAINING RALTEGRAVIR
PL394619A1 (en) Method of proteolysis, peptidase, a composition for use as a bactericide or bacteriostatic agent, a kit and the use of an active form of S. aureus LytM or a derivative thereof
PH12015500469A1 (en) High dose extended-release potassium citrate wax matrix tablet
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
UA65707U (en) Enamel
Oladele The Emergence of Social Networks on the Web as New Marketing Tools
UA52271U (en) Thermo-electric alloy
GB201105096D0 (en) Effervescent nootropic supplement tablet. Powdered cognitive enhancing effervescent tablet supplement including various nootropic compounds, including but not
TH146317A (en) Dry-coated tablets containing Tegafergimiracil and Othiracil Potassium.
UA55945U (en) Thermoelectric alloy
MX367692B (en) Biocide.